Product Briefs: IPF Breakthroughs, Bigger Labels For Velcade And Lymphoseek, Acura Appeal Denied
Executive Summary
Roche’s Esbriet and Boehringer’s Ofev become the first drugs approved by FDA for idiopathic pulmonary fibrosis; Velcade approved for first-line mantle cell lymphoma; Lymphoseek cleared for solid tumors; Acura mulls next steps after losing appeal on abuse-deterrent claim for Vycavert.
You may also be interested in...
Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences
InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
J.P. Morgan, Without The Parties, Reveals An Industry Ready To Get Down To Business
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: